DailyIQ
Last updatedjust now

BBIO·BridgeBio Pharma Inc.

$64.95
+1.65 (+2.61%)
After Hours
High
$65.36
Open
$63.34
Market Cap
12.38B
52W High
$94.51
Low
$62.86
P. Close
$64.95
P/E
-
52W Low
$52.75
Fwd P/E
600.68
DailyIQ Est.
$117.62
Inst. Ownership
51.0%
Short Interest
10.01%
Days to Cover
5.8
Technical Score (1D)
72
BULLISH
News Sentiment
70
BULLISH
On Oct 13, BridgeBio Pharma reaffirmed its strong buy rating, citing continued revenue expansion and multiple late‑stage pipeline assets. The company highlighted new data for Encaleret, a drug in development, and noted three forthcoming FDA reviews that could accelerate product approvals. These developments reinforced investor confidence in the firm’s growth trajectory and supported its positive outlook. The reaffirmation was based on the company’s solid revenue growth and the momentum of its pipeline, as reported by BridgeBio. The new Encaleret data and the upcoming FDA reviews were highlighted as key catalysts for the company’s future prospects.
LOW TARGET
$80 +23.2%
2 analysts
MEAN TARGET
$109 +67.9%
10 analysts
HIGH TARGET
$156 +140.2%
19 analysts
PRICE RANGE
$80.00 - $156.00
SB / B / H / S / SS
6/20/3/1/1
DAILYIQ EST.
$117.62 (+81.1%)
Bought (1Y)
0 shares
$0
Sold (1Y)
499,529 shares
$38.7M
Kumar NeilChief Executive Officer
Sell1,279 shares2026-09-17
Kumar NeilChief Executive Officer
Sell8,721 shares2026-09-17
Kumar NeilChief Executive Officer
Sell100 shares2026-08-19
Kumar NeilChief Executive Officer
Sell1,800 shares2026-08-19
Kumar NeilChief Executive Officer
Sell8,100 shares2026-08-19
40/ 100
Bearish
Overall: Bearish
✓Revenue growing year over year
✕Negative net margin
✕Negative operating cash flow
Net Margin
-146.0%
Revenue CAGR
52.1%
Current Ratio
2.77x
Debt / Equity
-0.96x
Return on Equity
35.1%

EPS

EstBeatMiss
$-1.00$-0.89$-0.78$-0.67$-0.55Q2'25Q3'26
QtrEstActual+/−
Q3'26$-0.63 - -
Q2'25$-0.60$-0.95-57.1%

Revenue

EstBeatMiss
$276M$276M$276M$276M$276MQ3'26
QtrEstActual+/−
Q3'26$276M - -
Q2'25 - - -

Market Data

BBIO Stock Snapshot

BULLISH72/100
$64.94−$0.01 (0.0%)
Market cap
12.38B
Day range
$62.86 – $65.36
News sentiment
70/100 · Bullish
Analyst target
$109.05 (+67.9%)
Consensus
Buy · 31 analysts
52-week range+23.1% off low · -31.3% from high
$52.75$94.51
Price $64.94 DailyIQ Est. $117.62

Momentum is working in BBIO's favour - it ranks in the upper part of DailyIQ's momentum universe. The stock is liquid enough that positioning changes get absorbed without distorting the trend.

Behaviour On Record

What BBIO's own history says about today's numbers

Realized volatility (21d)
43.8% 25th pct
Below its peak
-29.9%
vs 200-day average
-13.7%
Up days (1y)
51%

BridgeBio Pharma Inc. is currently running 43.8% annualised volatility over the last 21 sessions. Measured against BBIO's own 7 years of daily returns rather than a market-wide average, that is the 25th percentile — unusually subdued by its own history, against a typical reading of 57.6%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

BBIO is trading -29.9% below its running peak. Across 6 full years on file, its median worst-drawdown-in-a-year was -50.4%, and the deepest was -80.1% in 2021. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits -13.7% from its 200-day moving average. Against every other day in its history, that gap ranks at the 21st percentile — a narrower gap than it typically runs. Over the past year BBIO closed higher on 51% of sessions, and it is currently 1 session into a falling streak.

On October specifically: over 7 years of records, BBIO finished the month higher 5 of 7 times, with a median return of +2.5% and an average of +3.7%. Its strongest month historically has been June at +12.7% on average, its weakest September at -5.5%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: BBIO has opened more than 2% away from the prior close in 332 of 1,829 sessions (18.2% of the time), with the largest gaps running +20.9% and -12.2%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

All figures computed from 1,831 daily closes between 2019-06-27 and 2026-10-13, split-adjusted, recomputed daily. Percentiles are against BBIO's own 7-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of BBIO's sector?

BridgeBio Pharma Inc. sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading). Within its narrower Biotechnology industry group, BBIO ranks 9th of 15 tracked industries, improving.

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
82
Industry rank
#9 of 15

Options Market

What is the options market pricing for BBIO?

CallsPuts

For BridgeBio Pharma Inc.'s nearest expiry (2026-10-16, 2 days out), open interest is put-heavy, a defensive/bearish tilt (put/call ratio of 3.89), with at-the-money implied volatility around 50.9%. The options market is pricing roughly a ±4.3% move by that expiry — a range of about $62.49–$68.09.

Put/call ratio (2026-10-16)
3.89
ATM implied volatility
50.9%
Total open interest
12,875
Expected move by 2026-10-16
±4.3% ($62.49–$68.09)

Analyst Rating Changes

Are analysts turning bullish or bearish on BBIO?

Barclays most recently reiterated its rating on BridgeBio Pharma Inc. to Overweight on Oct 7, 2026 with a price target of $156 (from $157). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
Barclays — Overweight
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Oct 7, 2026BarclaysMaintainedOverweight$157 → $156
Sep 10, 2026HC Wainwright & Co.ReiteratedBuy$120
Sep 2, 2026HC Wainwright & Co.ReiteratedBuy$120
Sep 1, 2026MizuhoMaintainedOutperform$96 → $110
Aug 12, 2026Truist SecuritiesMaintainedBuy$102 → $107
Aug 12, 2026Canaccord GenuityMaintainedBuy$104 → $106
Aug 12, 2026JP MorganMaintainedOverweight$100 → $111
Aug 11, 2026B of A SecuritiesMaintainedBuy$101 → $104
Aug 11, 2026TD CowenMaintainedBuy$95 → $110
Aug 11, 2026Morgan StanleyMaintainedOverweight$98 → $97
Aug 11, 2026Piper SandlerMaintainedOverweight$111 → $115
Aug 11, 2026Wells FargoMaintainedOverweight$98 → $102

ETF holders

ETFs holding BBIO

News Sentiment Analysis

Sentiment gathered from recent headlines

70/100
Strong NegativeNeutralStrong Positive
BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
BridgeBio Pharma reaffirmed its strong buy stance, citing continued revenue expansion and multiple late‑stage pipeline assets. The company highlighted new data for Encaleret and noted three forthcoming FDA reviews that could accelerate product approvals. These developments reinforce investor confidence in the firm’s growth trajectory and support its positive outlook.
What did this article say?
BridgeBio Pharma announced that its investigational therapy Encaleret achieved clinically meaningful improvements in symptoms and bone turnover markers in a phase 3 trial for ADH1. The study demonstrated statistically significant benefits over placebo, supporting the drug’s potential to address unmet needs in this rare bone disorder. The positive data reinforce the company’s development pipeline and may strengthen investor confidence in its therapeutic strategy.
What did this article say?
BridgeBio reported that its drug Acoramidis achieved encouraging clinical outcomes in a real‑world study. The study demonstrated improved efficacy metrics compared to historical controls, suggesting the therapy may meet unmet needs in its target population. These findings support the company’s ongoing development plan and could strengthen its position in the market. The data were presented in a concise summary without detailed statistical analysis. The results are likely to be viewed positively by investors and clinicians alike.
What did this article say?
An independent, propensity‑matched analysis of 2,684 ATTR‑CM patients from Epic COSMOS found that acoramidis reduced the composite risk of death, hospitalization, new atrial fibrillation, and diuretic intensification by 18% versus tafamidis, with early separation of curves within one month.
What did this article say?
BridgeBio’s encaleret, which restores endogenous PTH secretion, achieved 100% symptom improvement in Phase 3 CALIBRATE participants versus 46% on standard care, and the FDA accepted its NDA with Priority Review, targeting action by May 2027.
What did this article say?
BridgeBio Pharma (BBIO) received FDA priority review for its oral drug infigratinib, targeting achondroplasia. The agency will aim to decide within six months, potentially accelerating market entry. Infigratinib offers a novel mechanism by directly inhibiting FGFR3, contrasting with existing injectable treatments. Phase III PROPEL 3 data showed a 2.1 cm/year height growth advantage over placebo. Approval would position BBIO as a pioneer in oral dwarfism therapy.
What did this article say?
Barclays analyst Eliana Merle retained an Overweight rating for BridgeBio Pharma (BBIO) while reducing the price target from $157 to $156. The downgrade reflects a modest reassessment of the company’s near‑term valuation. The change signals a slight negative outlook but does not alter the overall positive stance on the stock.
What did this article say?
BridgeBio Pharma announced it would present additional data from its Phase 3 CALIBRATE trial of encaleret for autosomal dominant hypocalcemia type 1 at the ASBMR 2026 Annual Meeting. The company plans to discuss patient‑reported outcomes and bone turnover markers, providing a more comprehensive view of the drug’s efficacy. It also intends to showcase findings from regional cascade genetic testing events aimed at delivering no‑cost testing to at‑risk relatives. The presentation is positioned as a step toward further clinical validation rather than a definitive breakthrough.
What did this article say?
BridgeBio Pharma presented new acoramidis data, including independent real‑world EHR comparisons, at the Heart Failure Society of America Annual Scientific Meeting. The company delivered one oral presentation, three rapid‑fire talks, and six poster sessions focused on transthyretin amyloid cardiomyopathy (ATTR‑CM). The data aim to strengthen the clinical evidence base for acoramidis in ATTR‑CM patients.
What did this article say?
BridgeBio Pharma announced a nationwide education initiative to raise awareness of transthyretin amyloid cardiomyopathy (ATTR-CM) on October 6, 2026. The program, launched via a YouTube premiere with community partners, aims to educate the public and healthcare providers about the underrecognized heart failure condition. By highlighting early symptoms and diagnostic challenges, BridgeBio seeks to improve timely recognition and treatment of ATTR-CM. The effort aligns with the company’s focus on genetic diseases and positions BridgeBio as a leader in patient education. No immediate financial or regulatory impact was indicated.

Technical Analysis

Real-time indicators across multiple timeframes

72
BULLISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $7.23B combined position · 14 adding, 11 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Vanguard Group Inc▲ Buy16,862,6918.58%$1.29B2026-01-29
Janus Henderson Group plc▲ Buy13,179,0136.71%$978.61M2026-05-18
BlackRock, Inc.▼ Sell10,287,1565.24%$766.19M2026-08-07
Viking Global Investors LP▼ Sell9,949,2195.07%$741.02M2026-08-14
Wellington Management Group LLP▲ Buy5,308,9242.70%$395.41M2026-08-14
Two Sigma Investments, LP▲ Buy4,722,1852.40%$351.71M2026-08-14
Citadel Advisors LLC▲ Buy3,760,0281.91%$280.05M2026-09-02
Invesco Ltd.▼ Sell3,700,9341.88%$275.65M2026-08-14
D. E. Shaw & Co., Inc.▲ Buy3,633,0071.85%$270.59M2026-08-14
Geode Capital Management, LLC▼ Sell3,418,4191.74%$254.67M2026-08-12
JPMorgan Chase & Co▲ Buy2,397,9951.22%$173.23M2026-08-12
Adage Capital Partners GP, L.L.C.▲ Buy2,252,0001.15%$167.73M2026-08-14
FMR LLC (Fidelity)▼ Sell2,061,3071.05%$153.53M2026-08-13
Goldman Sachs Group Inc▼ Sell1,814,6570.92%$135.16M2026-08-14
Norges Bank▲ Buy1,693,7730.86%$126.15M2026-08-12
Morgan Stanley▼ Sell1,693,6520.86%$126.14M2026-08-13
Point72 Asset Management, L.P.▲ Buy1,525,7820.78%$113.64M2026-08-14
AllianceBernstein L.P.▼ Sell1,453,5040.74%$107.94M2026-08-14
Bank of America Corp▼ Sell1,235,3800.63%$92.01M2026-08-14
Balyasny Asset Management L.P.▲ Buy1,230,0520.63%$91.61M2026-08-14
Squarepoint Ops LLC▲ Buy1,191,7320.61%$88.76M2026-08-14
Northern Trust Corp▼ Sell959,5130.49%$71.46M2026-08-13
Citigroup Inc▲ Buy864,1010.44%$64.36M2026-08-03
Renaissance Technologies LLC▲ Buy856,8460.44%$63.82M2026-08-13
Capital Research Global Investors▼ Sell700,1070.36%$52.14M2026-08-12
Q2 2026 flow:12.46M sh bought ($925.34M)9.77M sh sold ($727.45M)net +2.69M sh (+$197.89M)
Congressional Trading Activity
6 disclosed trades · ~$48.0K est. traded value · 5 buys, 1 sells
MemberChamberStateTypeAmountTradedFiled
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2026-09-292026-10-12
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-04-292026-05-08
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-03-192026-04-07
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-03-182026-04-07
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-03-032026-04-07
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-09-222025-10-10